12,372 trials
Hepatorenal Syndrome
Primary: Percentage of Participants With Confirmed Hepatorenal Syndrome (HRS) Reversal — 19.6; 13.1 percentage of participants
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) — 25.1; 49.9 percentage of participants — p=<0.001
Bipolar Youth Treated With Second-generation Antipsychotics
Primary: Body Mass Index (BMI) — 24.4; 26.3 kg/m^2
Delayed Sleep Phase Syndrome
Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510
HER-2 Positive Breast Cancer · Metastatic Neoplasm
Primary: Progression-free Survival (PFS) as Determined by Independent Radiological Review. — 5.8; 4.9 months — p=0.0334
Crohn's Disease
Primary: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 — 29.1; 49.5 percentage of participants — p=<0.0001
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) — 45.6; 47.1 percentage of participants — p=0.711
Neovascular Age-related Macular Degeneration (nAMD)
Primary: Number of Participants With Ocular Treatment Emergent Adverse Events — 2 Participants
Parkinson's Disease (PD)
Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083
Crohn Disease
Primary: Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14 — 11.9; 20.00; 27.3 Percentage of Particiapnts
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events — 88.2; 89.3; 81.0; 81.2 Percentage of Participants — p== 0.641
Juvenile Idiopahtic Arthritis
Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With…
Major Depressive Disorder
Primary: Change From Baseline in the 17-item HAM-D Total Score at Day 15 — -11.1; -11.5; -12.5 score on a scale — p=0.6638
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 — 2.39; 0.70 Percentage change — p=0.9047